The Prognostic Role of Prothrombin Time and Activated Partial Thromboplastin Time in Patients with Newly Diagnosed Multiple Myeloma

Table 2

Cox analysis (univariate and multivariate) of prognostic factors for OS.

	Univariate			Multivariate
	HR	95% CI	value	HR	95% CI	value
	1.477	1.063-2.054	0.020	1.737	0.982-3.073	0.058
	1.608	1.116-2.315	0.011
	0.589	0.417-0.832	0.003
	0.688	0.492-0.963	0.029
	1.547	1.133-2.114	0.006
	1.650	1.076-2.530	0.022	2.354	1.173-4.724	0.016
	2.749	1.787-4.229	0.000	1.890	0.991-3.606	0.053
Deep and full immunoparesis	1.734	1.124-2.676	0.013	2.298	1.351-3.909	0.002
Lengthened PT or APTT	2.100	1.525 2.893	0.000	3.183	1.803-5.617	0.000
	0.518	0.344-0.781	0.002
Light chain λ type	1.813	1.314-2.504	0.000	1.672	0.967-2.890	0.066
Induction regimes
Bortezomib based			0.421
IMiD based			0.610
Bortezomib and IMiD based			0.194
del(17p13)			0.054	2.296	1.007-5.235	0.048
t(14; 16)			0.833
t(4; 14)			0.071
ASCT	0.404	0.264-0.617	0.000	0.396	0.183-0.859	0.019

Abbreviations: PT: prothrombin time; APTT: activated partial thromboplastin time; IMiD: immunomodulatory; ASCT: autologous stem cell transplant.